

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
18 March 2004 (18.03.2004)

PCT

(10) International Publication Number
WO 2004/022076 A1

(51) International Patent Classification: **A61K 31/715, A61P 3/04**

(74) Agent: **VAN WESTENBRUGGE, Andries et al.**; Nederlands Octrooibureau, Scheveningseweg 82, P.O. Box 29720, NL-2502 LS The Hague (NL).

(21) International Application Number:
PCT/NL2003/000625

(22) International Filing Date:
9 September 2003 (09.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02078684.4 9 September 2002 (09.09.2002) EP

(71) Applicant (for all designated States except US): **NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO [NL/NL]; Schoemakersstraat 97, NL-2628 VK Delft (NL).**

(72) Inventors; and

(75) Inventors/Applicants (for US only): **EKHART, Peter, Frank [NL/NL]; Niessstraat 61, NL-1078 VJ Amsterdam (NL). VAN GEEL-SCHUTTEN, Gertridina, Hendrika [NL/NL]; Bosstraat 78, NL-3971 XG Driebergen (NL). VAN BINSEBERGE, Marie, Madelon [NL/NL]; Van Uvenweg 43, NL-6708 AE WAGENINGEN (NL). TIMMERMAN, Eef, Jan [NL/NL]; Voorstraat 13, NL-3931 HA Woudenberg (NL).**

(81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.**

(84) Designated States (regional): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).**

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **BRANCHED ALPHA-GLUCANS FOR WEIGHT MANAGEMENT**

(57) Abstract: Highly branched α -glucan having an average molar weight of at least 10^5 Da can be used for inducing or enhancing satiety and/or satiation in humans or animals by incorporation of the α -glucan into a liquid nutritional or pharmaceutical composition, preferably together with a food protein. The α -glucan induces a viscosity increase upon lowering the pH. The degree of branching of the α -glucan is at least 8%. Such α -glucans can be obtained e.g. by fermentation of lactic acid bacteria strains having glucosyltransferase activity on a sucrose substrate.

WO 2004/022076

PCT/NL2003/000625

1

BRANCHED ALPHA-GLUCANS FOR WEIGHT MANAGEMENT

Field of the invention

[0001] The invention is in the field of body weight management. In particular, the invention is concerned with a method for inducing satiety feeling by incorporating a satiety-inducing compound into a liquid product suitable for human consumption.

Background of the invention

[0002] The incidence of obesity-related diseases is continuously rising among the developed populations, affecting about 250 million people world-wide with a double digit growth annually. Also incidence for overweight is increasing with a prevalence of 800 million people world-wide.

[0003] In their search for effective solutions for the global health problem of obesity among the Western population, both the pharmaceutical and the food industry have developed several concepts for inducing or extending satiety feeling for the consumer.

[0004] The pharmaceutical industry has aimed at developing targeted specific inhibitors of the digestive enzymes, fat replacers or burners. Examples of pharmaceutical active compounds affecting satiety feeling like sibutramine (Roche) and digestive enzymes like Orlistat (Knoll/BASF) or Acarbose (Bayer, US 4,062,950). Common dosage forms for these active compounds are powders and tablets.

[0005] The food industry has focused on the development of meal replacers and supplements containing satiety-inducing ingredients, reduced energy components and also burners. Examples of meal replacers marketed by food industry are Slimfast (Unilever), Profiel (Numico), Ensure (Abbott) and Modifast (Novartis). These products are presented in a solid form, for example a food bar, a powder blend, a bakery product or in liquid forms like a nutritious drink.

[0006] Burners used in food products but also supplements are for example caffeine combined with ephedrine, increasing the energy metabolism. Examples of reduced energy components used in food products are sucrose esters like Olestra, dietary fibres and reduced fat products. Dietary fibres can also induce a slow down of the stomach emptying and a slow uptake of nutrients.

[0007] The combined portfolio of commercial products offered have appeared to be little effective on the management of weight in human volunteer studies, with some exceptions in the food and pharma market. Especially for the meal replacers little proof of principle has been demonstrated (Critical reviews in food science and nutrition, (2001), 41 (1), 45-70).

[0008] Solutions for satiety inducement known in the art are for example mentioned in WO 01/30231 describing a proteinase inhibitor, claimed to induce a feed-back mechanism for CCK production. CCK is known to be related to satiation. The common

WO 2004/022076

PCT/NL2003/000625

2

food ingredients known to affect satiety and satiation can also be combined in order to gain maximum effect on satiety feeling like is done by Pacific Health Laboratories (US 6,207,638) in their Satiatrol product line. The product contains protein, long chain fatty acids, calcium and soluble and insoluble fibres claimed to affect the production of cholecystokinin (CCK). US 4,833,128 describes a formula with a high phenylalanine content also claimed to stimulate CCK production by the body.

[0009] Other active compounds claimed to affect satiety feeling directly are described in WO 97/31943 (GLP-2 peptide), WO 98/20895 (GLP-1 peptide), WO 00/22937 (leptin), WO 99/55331 (α -lipoic acid), WO 95/29676 (cotinine), GB 2165452 (pseudoephedrine) and WO 01/20991 (phytochemicals).

[0010] Several carrier systems are described in order to create a targeted delivery of particular active components in the digestive tract like for example WO 01/17377 and DE 19942417 both using uronic acid containing polysaccharides optionally crosslinked as a carrier for actives, WO 93/24113 using formulas creating delayed uptake of nutrients in order to suppress hunger feeling, and US 5,753,253 employing pH sensitive coatings to deliver actives in the ileum.

[0011] Strategies aiming at inhibition of digestive enzymes have been described in US 5,726,291 (α -amylase) and lipase inhibitors (Orlistat).

[0012] Another route for inhibiting glucose uptake by the human digestive tract has been described in patent application US 2002/0037577, claiming the use of probiotic micro-organisms like *L. reuteri* in order to capture digestible sugars and to convert these into non-digestible polysaccharides. The probiotic micro-organisms are preferably dosed in enteric coated capsule designed to release the micro-organisms in the small intestine.

[0013] Finally strategies affecting the gastric emptying or delayed uptake of nutrients are described in US 4,689,219 (xanthan - locust bean gum blends), WO 00/22937 (gelled protein particles for delayed uptake of amino acids) and EP 0471217 (double gelatine layer for release of stomach filling agent).

[0014] The solutions described in the art have mainly been developed using solid dosage forms for the active compounds being either a compound directly affecting satiety feeling, an inhibitor, a slow release compound or a burner. On the other hand, liquid formulas are limited and are focussed on the delivery of particular actives or they are part of the meal replacers like the designer drinks as Slim fast or Ensure. For the liquid formulas it would be very desirable to have an active compound which can be formulated in a liquid product without affecting the preferred sensory attributes of the drink. This active compound should preferably demonstrate no excessive thickening or gelling properties in the liquid product. However if this compound could also create satiation after entering the stomach a new concept for the development of liquid weight management formulas would become available.

WO 2004/022076

PCT/NL2003/000625

3

[0015] Well known examples of compounds claimed to have satiety-inducing effects are hydrocolloids incorporated in solid formulas, creating a significant thickening or gelling effect in the stomach. This leads to a feeling of satiety and provides possibilities to manage the delivery of nutrients or other active compounds to the ileum. Hydrocolloids used in liquid products have a low level of dosage ranging between 0.01 and 1 wt% and will not demonstrate an increase in viscosity after entering the stomach, relative to a product not containing any hydrocolloid. A theoretical exception to this rule is formed by particular low methylated pectins which are able to increase the viscosity in case the acidity is increased. In practise this concept can not be used due to the high sensitivity of this type of pectin for calcium cations, which destroys the acid effect on viscosity (Gilsenan, P.M. thermally reversible acid induced gelation of low-methoxy pectin, (1999), 41, 339-349.

[0016] Also insoluble dietary fibres like wheat fibre or apple fibres are known to be effective in creating a saturated feeling if used in a liquid product. Disadvantage of these insoluble fibres is the limited level of dosage in liquid products due to destabilisation effects in the liquid product or undesired appearance of the liquid product. These undesired appearances include precipitation of fibre and cloudiness.

[0017] Additionally the water binding effect of dietary fibres is limited if dosed via a liquid product in contrast to solid products. Additionally other active compounds can bind irreversibly to insoluble dietary fibres reducing their nutritional efficacy.

[0018] The limitations in the art described have created the need for a polysaccharide which can be used to stabilise liquid products without the problem of undesired appearances, unwanted changes in texture, intolerance problems for the consumer, the caloric content and with the ability to increase the residence time in the stomach. The current invention provides a solution for this need as explained in the description of the invention.

Description of the invention

[0019] It was found that satiety feeling can be induced by incorporating into a liquid product for human consumption a highly branched α -glucan. When consumed by a person, the viscosity of the liquid product drastically increases triggered by the low pH conditions of the stomach. The method is effective when using varying levels of glucan, e.g. ranging between 1 and 10 wt% on total liquid protein-containing product, in particular in the presence of a protein. Thus, the invention pertains to the use of branched α -glucans for preparing a nutritional or pharmaceutical composition suitable for satiation or enhancing satiety in a human.

[0020] It was observed that α -glucans having a certain elevated degree of branching combined with a particular molecular weight surprisingly induce a thickening effect in case of an increase of the acidity in the product, especially in the presence of protein.

WO 2004/022076

PCT/NL2003/000625

4

This effect is favourable for the formulation of liquid products adding stabilising and texturising functionality in the drink without affecting the preferred sensory attributes and appearance. After lowering of the pH, a significant thickening effect occurs leading to a prolonged and enhanced satiation and satiety feeling in contrast to existing liquid product formulations using polysaccharides as an active compound.

[0021] The α -glucans to be used according to the invention should have a degree of branching of at least 8%. The degree of branching is defined as the total number of branching anhydroglucose units (AGU), i.e. AGU being bound to three other units, with respect to the total number of AGU of a molecule. The degree of branching can be determined by methods known in the art, like selective hydrolysis using isoamylase followed by a coulometric titration with iodine, or methylation of the polysaccharide followed by hydrolysis and gas chromatography analysis. The preferred minimum degree of branching is 10%, more preferred at least 12%, up to e.g. 24%.

[0022] In general, a branched polysaccharide consists of three types of units, (a) terminal units, being bound to one other unit only, (b) chain units, being bound to two other units, and (c) branching units, being bound to three other units. The total number of branching units is equal to the total number of terminal units minus two. Thus, in polysaccharides of a certain length (e.g. over about 1,000 units, i.e. with a molar weight over 160,000) the percentage of branching units becomes about equal to the percentage of terminal units.

[0023] As methods of determining the precise proportion of branching and terminal units may result in slightly different values from method one to another, the degree of branching can also be defined as the percentage of branching units plus the percentage of terminal units, divided by two.

[0024] The glucans to be used according to the invention contain, as a result of their branched nature, at least two types of linking one AGU to another. The type may be 1,2-linking, 1,3-linking, 1,4-linking or 1,6-linking. The glucans of the invention contain at least 1,6-linkages. Preferably the branched α -glucans contain both 1,4-linkages and 1,6-linkages, the branching units being 1,4,6-linked and amounting to at least 8% of the AGU. The glucans may also contain 1,3 and 1,6 linkages such as the mutan-type glucans described in WO 03/008618. The glucans may have an average molecular weight of at least 10^5 Da, preferably at least $5 \cdot 10^5$ Da, more preferably at least $2.5 \cdot 10^6$ Da, up to e.g. 10^9 , in particular up to 10^8 Da. The glucans are preferably non-ionic, and more preferably non-derivatised, although a degree of substitution with e.g. acyl groups, carboxyl groups, hydroxyalkyl groups up to about 5% will be acceptable.

[0025] Preferably the glucans to be used can be obtained from sucrose by glucosyl transferase activity (*de novo* synthesis), for example expressed by food approved micro-organisms like *L. reuteri* (WO 01/90372). Alternatively, the highly branched α -glucans can be derived by modification of commonly available glucans - like starch, amylo-

WO 2004/022076

5

PCT/NL2003/000625

pectin or glycogen - having an insufficient degree of branching, using suitable micro-organisms or their branching enzymes (EC 2.4.1.18) capable of producing the desired degree of branching. Examples of suitable branching enzymes are α -(1,4)-D-glucan: α -(1,4)glucan 6-glycosyltransferases and α -(1,4)-D-glucan: orthophosphate α -glycosyl-
5 transferases (EC 2.4.1.1). Also blends of different highly branched α -glucans can be used.

[0026] It is also possible to produce the highly branched glucans by *de novo* synthesis from glucose or (phosphorylated) glucose derivatives using a combination of a glucan synthesising enzyme and a branching enzyme, or by synthesis from sucrose using a
10 combination of an amylosucrase and a branching enzyme. As an example, highly branched α -(1,4)(1,6) glucans can be obtained from sucrose by the combined action of an amylosucrase and an α -(1,4)-D-glucan: α -(1,4)glucan 6-glycosyltransferase optionally expressed in modified crops. A degree of branching up to 35% can be obtained as described in EP-A-1117802 (WO 00/22140, PlantTec).

15 [0027] Glycogen is an abundant endogenic energy storage molecule in higher life forms and particular bacteria and has a degree of branching of about 8-12% (Voet and Voet, Biochemistry, John Wiley & Sons, 1990). Glycogen is synthesised by glucosyl transferases using activated glucose as a substrate, being an economically unattractive process for industrial purposes. Other means to obtain highly branched α -(1,4)(1,6)
20 glucans is offered via several enzymatic routes (in planta or in situ with micro-organisms or their enzymes as illustrated in EP-A-1117802).

[0028] The highly branched α -glucans obtained by the action of glucosyltransferase on sucrose as described in WO 01/90372 have a molecular weight of at least 10^7 as determined by SEC-MALLS-RI (Van Geel, I. *et al. Appl. Environ. Microbiol.* (1999)
25 65, 3008-3014) and a very compact configuration. They are referred to as "reuteran". This compactness is demonstrated by the radius of gyration, showing a level of only 35 nm. The degree of branching can exceed 15% for these particular glucans. The thickening effect demonstrated for reuteran as a function of the pH lowering using hydrochloric acid can be explained by the Hofmeister effect as reviewed by Collins
30 (Collins, K.D. Washabaugh, M.W., (1985), *Quart. Rev. Biophys.* 18, 323). The increase in water structure disrupting chloride ion concentration leads to a better water binding by the polysaccharide reuteran. The improved water binding is expected to result in the observed viscosity increase, which is relevant for stomach conditions. In contrast, if water structure improving electrolytes are used like citrate, reuteran will be deprived of
35 its water binding capacity as is demonstrated in the examples below.

[0029] The glucans to be used according to the invention should have a reduced digestibility, i.e. increased resistance to degradation by intestinal enzymes, compared to e.g. starch. Preferably, the digestibility (expressed as percentage glucose release in

WO 2004/022076

6

PCT/NL2003/000625

jejunum and ileum e.g. in the TNO gastro-intestinal model for the small intestine: Minekus *et al*, Alternatives to Laboratory Animals (ATLA) 23: 197-209) should be less than 30% compared to native starch. Thus, the glucans have nutritional fibre characteristics.

5 [0030] The highly branched glucans can be used as an ingredient in products used for medical, nutraceutical and food applications, especially liquid products preferably also containing a proteinaceous compound. The glucan can be dosed at a level ranging from 0.5 up to 10 wt.%, preferably from 1 to 8 wt% (w/w), preferably in combination with a food or pharma grade protein present at levels ranging between 0 up to 15% (w/w) on
10 total product.

[0031] In a preferred embodiment of the invention highly branched $\alpha(1,4)(1,6)$ glucans are used in liquid products for example a drink or beverage, preferably also containing proteins. More preferably this drink is a flavoured or fermented milk drink such as a yoghurt-like drink. Advantageously, the drink may be inoculated with a lactic acid
15 bacterium, such as *Lactobacillus reuteri*, expressing said glucosyltransferase activity combined with a sucrose substrate. The drink is stabilised and textured by the soluble $\alpha(1,4)(1,6)$ -glucan while at the same time a significant thickening effect is obtained after entering the acidic conditions of the stomach. Other suitable forms of the liquid composition of the invention include fruit drinks, other dairy products, soups, sauces, or
20 specially designed solutions or dispersions. Where reference is made herein to a liquid composition or liquid product, this naturally extends to a non-liquid or semi-liquid product having the same weight ratios of its ingredients, but a different (i.e. lower) solvent content. Thus a liquid product also covers a concentrate or a dry form which after suitable dilution or addition of water or other aqueous solvents and possibly further
25 ingredients produces a liquid composition which is ready for use.

[0032] The liquid composition of the invention preferably also contains a protein, which can be any food or pharma grade protein showing a good stability and solubility at pH 3-6; such protein is referred to herein as "food protein". Suitable food proteins include milk proteins such as casein and whey proteins, soy, pea, fungal, egg protein
30 and gelatine, or their hydrolysates. The protein may be incorporated in the liquid composition at a level of e.g. 0.5 - 15 g per 100 g, preferably 2-10 wt.%. The preferred weight ratio between α -glucan and protein is between 0.02 and 10, preferably between 0.2 and 5.

[0033] The composition may advantageously also contain further nutritional fibres, e.g.
35 soluble fermentable or non-fermentable fibres such as pectin, gum arabic, inulin, arabinans, galactomannans or oligosaccharides, and/or insoluble fibres such as cellulose, other β -glucans and hemicellulose, e.g. at a level of 0.5-5 g per 100 g. The weight ratio between the poorly digestible branched α -1,6 linkages-containing glucans to be used according to the invention and other nutritional fibres is preferably between

WO 2004/022076

PCT/NL2003/000625

7

19 and 0.2, more preferably between 9 and 0.5. The composition may further contain fats, fat replacers, other weight management components, emulsifiers, thickeners, stabilisers, flavours, colorants, salts, vitamins, and other food components, such as fruits, nuts, cereals, etc.

5 [0034] The invention also pertains to method of inducing satiety to a person in need thereof, in particular for weight management purposes or for preventing or curing obesity, by administering the branched α -glucan described above, preferably in the presence of proteins, typically in the form of a drink containing the α -glucan at a level of e.g. 1-10% by weight. The dosage can be adapted to the required satiety and to
10 further individual needs and conditions of the subject. For example, an amount from 1 g per day can be administered up to e.g. 250 g per day, in a single dosage, or preferably divided over 2-4 daily dosages. Preferred amounts are between 5 and 50 g of α -glucan per day. Advantageously, the glucan is administered on a regular, repeated basis, e.g. for at least 7 days or more.

15 [0035] Advantages of the present invention are created by improved satiety feeling for its consumers, better product appearance, lower caloric content, lower formulation costs also due to little legislative barriers and a clean labelling for the target food products using the ingredient.

[0036] Additional advantages in using these compounds for the application targeted are
20 found in the fact that no heat treatment needs to be applied in order to functionalise the ingredient like for granular amylopectin starch and no retrogradation phenomena are observed in time leading to an improved stability. Also, the detrimental effects of human endogenous amylase activity on the thickening effect are not observed for reuteran, which also leads to a low glycemic index.

25 [0037] *In vitro* experiments have demonstrated that this pH-triggered thickening effect results in an instantaneous increase of the viscosity. This viscosity effect creates opportunities for product developers to incorporate other active components in the drink which need a retained release from the stomach into the ileum.

[0038] Other advantages provided by the highly branched α -glucan is the limited
30 degradation during passage through the small intestine lowering the glycemic index of the product. This makes it also a very suitable ingredient for formulations used by diabetics.

[0039] Other embodiments of the invention are the use of highly branched α -glucan in
35 the formulation of solid or semi-solid products creating also a viscosifying effect in the stomach. Also applications in feed or pet food are part of the invention.

WO 2004/022076

PCT/NL2003/000625

8

Example 1. Production of reuteran

Strain Lb 35-5 was produced as described in WO 01/90372 and subsequently concentrated and washed by centrifugation using an 0.1 M acetic acid buffer. The cells were anaerobically suspended in a 150g/l sucrose 0.1 M acetic acid buffer pH 5.5 overnight under stirring. The following day the cells were removed by centrifugation and the reuteran was washed using diafiltration in a 150 kDa ultrafiltration unit, until unreacted sucrose could not be detected anymore. The retentate was freeze-dried and the resulting reuteran was used for further experiments.

Example 2. Physical properties in water and milk drink

Reuteran obtained as described according to example 1 was added at a 5 wt.% level to a commercial milk drink with a pH of 4 (Friesland Coberco Dairy Foods: Frisly no sugar added, multi-fruit flavour). The original milk drink and the milk drink with reuteran were evaluated for their viscosity as a function of time and concentration of HCl. For this purpose the viscosity of the drinks was measured using a Rheometrics RFSII dynamic rheometer with a Couette DIN geometry at a temperature of 37°. As a reference also a 7.5 wt% reuteran solution in water with a calcium level of 0.2621 g/l $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ was made with a pH of 6.8. Each sample either was compensated for the volume of 4 M HCl added to the acidified samples. At first a strain sweep was executed between 0.1-100% at 10 rad/s for the milk drink in order to select a deformation in the linear region for the time sweep at 10 rad/s (for the acidified samples) or the frequency sweep between 0.1-100 rad/s (for the original solutions). The measurements were performed directly after sample preparation.

Table 1 shows the thickening effect for the original milk drink as well as for the milk drink containing 5 wt% reuteran as a function of change in HCl concentration and time. The thickening effect triggered by the drop in pH is drastically amplified by reuteran. The milk drink containing reuteran demonstrates a very useful thickening effect due to increased HCl concentration at a physiologically relevant level. Also the pure reuteran solution in water shows a clear thickening effect due to an increase in HCl concentration as can be derived from the frequency sweeps collected in figure 1 (Frequency sweep for a 7.5wt% reuteran solution in water (10° DH) at two different pH values). The resulting viscosities at 10 rad/s are 0.24 at pH 6.8 and 0.86 after pH drop (pH 2).

Table 1: Viscosity (Pa.s) of milk drink at 10 rad/s

	pH 4	pH 2, 0 h	pH 2, 1 h	pH 2, 2 h	pH 2, 3 h
milk drink	0.01	0.01	0.02	0.025	0.03
milk drink with 5% reuteran	0.25	0.37	0.75	0.84	0.88

WO 2004/022076

PCT/NL2003/000625

9

Example 3. Thickening effect as a function of the degree of branching

In order to demonstrate the importance of the degree of branching the following experiment was designed. Two branched α -glucans were selected being reuteran with a level of $\alpha(1,4,6)$ linked AGU of 16% (Mw $3.5 \cdot 10^6$) (van Geel I. et al., *Appl. Environ. Microbiol.* (1999), 65, 3008-3014) and glycogen obtained from Merck (order nr. 4202) with a level of $\alpha(1,4,6)$ linked AGU of 8% (Mw $0.27 \cdot 10^6$). As a control a pullulan (non-branched) containing 31% $\alpha(1,6)$ linked AGU (Mw $3.5 \cdot 10^6$) was also tested.

The three polysaccharides were dosed in the milk drink as used in example 2 at a 5wt% level. For the three milk drinks and a reference a frequency sweep was executed as described in example 2. The viscosity at 10 rad/s for the non-acidified drinks was derived from a separate frequency sweep as described before.

The results for these measurements are collected in table 2 showing the viscosity at 10 rad/s as these were derived from the frequency sweeps executed for the acidified and non-acidified drinks, respectively. The α -glucans containing $\alpha(1,4,6)$ linked AGU show a clear pH triggered thickening effect. In contrast, the pullulan not having $\alpha(1,4,6)$ linked AGU's does not demonstrate a thickening effect in the milk drink upon pH lowering.

Table 2: Viscosity (Pa.s) of milk drink with different glucans

	Viscosity (Pa.s)		Viscosity increase
	pH 4	pH 2	
5 wt% reuteran in milk drink	0.2553	0.3695	45 %
5 wt% glycogen in milk drink	0.0064	0.0411	540 %
5 wt% pullulan in milk drink	0.8051	0.3661	-55 %

Example 4

Different amounts of reuteran (0, 1, 2 and 5% w/w) were added to Slim-Fast (commercially available) and thermostated in a water bath at 37 °C. The pH of the samples was adjusted to pH 2 by adding 4M HCl. For the controls (no pH lowering), an equal amount of water (10 DH) was added. The rheology of the samples was measured using a Rheometrics RFS II with Couette DIN geometry at 37 °C. After thermostating, a strain sweep was performed at 37°C. The pH-dependent thickening effects are summarised in table 3 showing the critical G^* values.

WO 2004/022076

10

PCT/NL2003/000625

Table 3: G values (Pa) Slim-Fast with different amounts of reuteran

G* critical (Pa)	G* (Pa)
5% reuteran in Slim-Fast	8.0
Slim-Fast pH2 control	15.5
1% reuteran in Slim-Fast pH2	20.0
2% reuteran in Slim-Fast pH2	29.5
5% reuteran in Slim-Fast pH2	47.0

WO 2004/022076

PCT/NL2003/000625

11


Claims

1. Use of a branched α -glucan having an average molar weight of at least 10^5 Da and having a degree of branching of at least 8%, for preparing a liquid nutritional or pharmaceutical composition suitable for inducing or enhancing satiety and/or satiation.
2. Use according to claim 1, wherein the α -glucan has a degree of branching of at least 10%, preferably at least 12%.
3. Use according to claim 1 or 2, wherein the α -glucan has an average molar weight of between $5 \cdot 10^5$ and 10^8 Da.
4. Use according to any one of claims 1-3, wherein the α -glucan contains $\alpha(1,4)$ and $\alpha(1,6)$ linkages.
5. Use according to any one of claims 1-4, wherein the α -glucan is non-ionic.
6. Use according to any one of claims 1-5, wherein the α -glucan is produced by enzymatic glucosyl transfer from sucrose.
7. Use according to any one of claims 1-6, wherein the α -glucan is used in a concentration of 1-10 % (by weight).
8. Use according to any one of claims 1-7, wherein the α -glucan is combined with a protein, especially a processed milk or soy protein.
9. Use according to any one of claims 1-8, wherein an aqueous solution of 7.5 wt.% the α -glucan at pH 2 shows an increase in viscosity of at least 1.5 times compared to the viscosity at pH 6.8, measured at 10 rad/s.
10. Liquid food composition, containing 1-10 wt.% of an α -glucan having an average molar weight of at least 10^5 Da and having a degree of branching of at least 8%, and at least 1 wt.% of a food protein.
11. A method of inducing satiety and satiation in a person in need thereof, comprising repeatedly administering to that person an effective amount of a branched α -glucan having an average molar weight of at least 10^5 Da.

WO 2004/022076

PCT/NL2003/000625

1/1



SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/NL J3/00625

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/715 A61P3/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 719 783 A (EZAKI GLICO CO) 3 July 1996 (1996-07-03) claims 5,10,16 page 28, line 30 - line 31 page 11, line 45	1-11
Y	WO 82 03329 A (SILK DAVID B A ;BEIGLER MYRON A (US)) 14 October 1982 (1982-10-14) claim 16 page 18, 2nd paragraph	1-11
Y	EP 0 550 060 A (KANEGAFUCHI CHEMICAL IND) 7 July 1993 (1993-07-07) claim 4 page 4, line 5 page 3, line 36 - line 38	1-11

-/--



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

S document member of the same patent family

Date of the actual completion of the international search

6 January 2004

Date of mailing of the international search report

13/01/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl
Fax (+31-70) 340-3016

Authorized officer

Beranová, P

INTERNATIONAL SEARCH REPORT

Internat. application No
PCT/NL J3/00625

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 2002/035089 A1 (HADVARY PAUL ET AL) 21 March 2002 (2002-03-21) claims 4,5,28 paragraph '0059!	1-11
A	EP 0 506 166 A (UNILEVER PLC ;UNILEVER NV (NL)) 30 September 1992 (1992-09-30) page 2, line 10 - line 15	
A	FR 2 486 400 A (UNIVABLOT) 15 January 1982 (1982-01-15) claims 7-9,11,14,15	
A	DE 198 60 375 A (AVENTIS RES & TECH GMBH & CO) 6 July 2000 (2000-07-06) claim 1	

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

 Internat. application No.
PCT/NL 03/00625
Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 11 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/NL J3/00625

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0719783	A	03-07-1996	JP 3240102 B2	17-12-2001
			JP 8104696 A	23-04-1996
			AT 220406 T	15-07-2002
			DE 69527343 D1	14-08-2002
			DE 69527343 T2	27-03-2003
			DK 719783 T3	04-11-2002
			EP 0719783 A2	03-07-1996
			JP 2002020398 A	23-01-2002
			JP 2002037796 A	06-02-2002
			US 5861048 A	19-01-1999
			US 6268182 B1	31-07-2001
WO 8203329	A	14-10-1982	AU 8337482 A	19-10-1982
			BE 892701 A1	16-07-1982
			EP 0075594 A1	06-04-1983
			WO 8203329 A1	14-10-1982
EP 0550060	A	07-07-1993	US 5268367 A	07-12-1993
			EP 0550060 A1	07-07-1993
			JP 6065082 A	08-03-1994
US 2002035089	A1	21-03-2002	AU 8969901 A	13-02-2002
			BR 0112799 A	01-07-2003
			CA 2416901 A1	07-02-2002
			CN 1444495 T	24-09-2003
			WO 0209816 A2	07-02-2002
			EP 1307264 A2	07-05-2003
			HU 0301281 A2	28-08-2003
			NO 20030418 A	27-01-2003
EP 0506166	A	30-09-1992	CA 2063784 A1	26-09-1992
			EP 0506166 A2	30-09-1992
			JP 5236908 A	17-09-1993
FR 2486400	A	15-01-1982	FR 2486400 A1	15-01-1982
DE 19860375	A	06-07-2000	DE 19860375 A1	06-07-2000
			AU 1387800 A	31-07-2000
			WO 0038537 A1	06-07-2000
			EP 1139789 A1	10-10-2001
			JP 2002533107 T	08-10-2002